Showing 6131-6140 of 9119 results for "".
- Data Show Acne Patients Don't Understand Risks Associated with Antibiotic Treatmenthttps://practicaldermatology.com/news/data-show-acne-patients-dont-understand-risks-associated-with-antibiotic-treatment/2458805/Widespread and inappropriate use of antibiotics continues to be a problems in the US leading to antibiotic resistance issues. While most people understand how the overuse of antibiotics to treat viral infections contributes to this issue, according to Galderma, new data reveal that acne patients
- AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Deviceshttps://practicaldermatology.com/news/ama-calls-for-ban-on-direct-to-consumer-advertising-of-prescription-drugs-and-medical-devices/2458806/Physicians at the Interim Meeting of the American Medical Association (AMA) adopted new policy aimed at driving solutions to make prescription drugs more affordable. Physicians cited concerns that a growing proliferation of ads is driving demand for expensive treatments despite the clinic
- GSK: Positive Phase 3 Results for Benlysta® In Patients with Systemic Lupus Erythematosushttps://practicaldermatology.com/news/gsk-positive-results-phase-3-results-for-benlysta-in-patients-systemic-lupus-erythematosus/2458812/Results from the BLISS-SC Phase 3 pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) show that Benlysta®(belimumab) 200mg administered weekly via subcutaneous injection plus
- Immune Pharmaceuticals: FDA Accepts IND Application for Bertilimumab for Bullous Pemphigoidhttps://practicaldermatology.com/news/immune-pharmaceuticals-fda-accepts-ind-application-for-bertilimumab-for-bullous-pemphigoid/2458813/Immune Pharmaceuticals, Inc. has indicated that the FDA has accepted the Company's Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). This FDA acceptance enables the Company to expand recruitme
- Diplomat Pharmacy to Dispense Cotellic®https://practicaldermatology.com/news/diplomat-pharmacy-to-dispense-cotellic/2458816/Diplomat Pharmacy, Inc. will dispense Cotellic® (cobimetinib) in combination with the BRAF inhibitor Zelboraf® (vemurafenib) to treat patients with advanced melanoma that is unrespectable or metastatic. The com
- LEO Pharma to Acquire Global Dermatology Portfolio from Astellashttps://practicaldermatology.com/news/leo-pharma-to-acquire-global-dermatology-portfolio-from-astellas/2458818/LEO Pharma A/S and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. Under the terms of the agreement, the assets and associated respon
- Syneron Appoints Jeff Nardoci as President of North America Body Shaping Grouphttps://practicaldermatology.com/news/syneron-appoints-jeff-nardoci-as-president-of-north-america-body-shaping-group/2458820/Syneron Medical Ltd., a leading global aesthetic device company, appointed Jeff Nardoci as President of its North America Body Shaping Group. In this position, Mr. Nardoci will be responsible for the development and execution of the company's growth strategies for UltraShape and VelaShape. He
- Lumenis UltraPulse Technology is Being Used to Treat Kim Phuc “The Girl in the Picture”https://practicaldermatology.com/news/lumenis-ultrapulse-technology-is-being-used-to-treat-kim-phuc-the-girl-in-the-picture/2458821/Lumenis Ltd.’s UltraPulse laser is being used by Jill Waibel, MD to treat scars on Kim Phuc, a survivor of a Vietnam War bombing in 1972. The UltraPulse was chosen for its effectiveness in laser scar revision therapy that is needed to penetrate deep into the thick scars. Kim Phuc, a
- Provectus Biopharmaceuticals: Immune Mechanism of Action Data for PV-10 Presented at Society for Immunotherapy of Cancer Annual Meetinghttps://practicaldermatology.com/news/provectus-biopharmaceuticals-immune-mechanism-of-action-data-for-pv-10-presented-at-society-for-immunotherapy-of-cancer-annual-meeting/2458823/Researchers from Moffitt Cancer Center in Tampa, FL, presented a poster titled, “Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1,” at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, MD, accor
- Revision Skincare Announces Partnership with World Champion Gymnast Aly Raismanhttps://practicaldermatology.com/news/revision-skincare-announces-partnership-with-world-champion-gymnast-aly-raisman/2458824/World Champion gymnast and three-time Olympic gold medalist Aly Raisman is now an ambassador for the Revision Skincare brand. “My partnership with Revision Skincare is very important to me because I used to struggle with skin problems before using their products,” Ms. Raisman